We’re growing! Re-Vana Therapeutics is excited to welcome six new team members:

Hans Christinger – Chief Business Officer
Jim McIlroy – Vice President, Quality
JJ Hancock – Vice President, R&D
Daphne Doucet – Chief of Staff
Aaron Phillips – Formulation Scientist
Naomi Tully – Laboratory Scientist

Re-Vana is thrilled to welcome Hans Christinger as Chief Business Officer! With 30+ years of biotech leadership, from Roche & Abbott to founding GRIN & Modig, Hans brings vision, experience & passion to drive our next stage of growth.

Re-Vana is pleased to announce that our CEO, Michael O'Rourke, will present at OIS Retina Innovation Summit on July 29 at 11 AM during the Spotlight on Drug Delivery. #OIS2025

Great insights and conversations at #Eyecelerator Park City! Thanks to all who connected with Re-Vana and to Michael J. O'Rourke for representing us on the S5 Drug Delivery Panel. Excited about the future of long-acting ophthalmic biologics. #ophthalmology www.linkedin.com/feed/update/...

Re-Vana’s CEO will join the Retina Unplugged panel at Retina World Congress, May 8–11 in Ft. Lauderdale. #ophthalmology #innovation

www.linkedin.com/feed/update/...

Re-Vana’s CEO & COO will attend Eyecelerator @ Park City May 2. Catch Michael J. O’Rourke on the S5 Drug Delivery Panel! #ophthalmology #eyecelerator www.linkedin.com/feed/update/...

2025 is off to a great start at Re-Vana Therapeutics! We're advancing sustained-biologics for retina diseases, including a 6-month anti-VEGF implant. Plus, we’re celebrating new team members & well-earned promotions! 👏 Read the full post on our LinkedIn: www.linkedin.com/posts/re-van...